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Edited by Jesus AvilaAbstract Intranuclear ﬁbrils due to poly-alanine expansions in
the N-terminal domain of the poly(A) binding protein PABPN1
correlate with the disease oculopharyngeal muscular dystrophy
(OPMD). For monitoring ﬁbril formation by ﬂuorescence and
real-time NMR spectroscopy, tryptophans were introduced
either into the middle or C-terminal of the poly-alanine segment.
The kinetics of ﬁbril formation which were monitored by ﬂuores-
cence spectroscopy were matched by real-time NMR kinetics.
Our results show that ﬁbril formation is concomitant with the
burial of the tryptophans in the ﬁbrillar core. Since no soluble
pre-ﬁbrillar intermediate(s) was detected, ﬁbril formation of this
domain may be regarded as a two state conversion from an un-
folded soluble into folded insoluble species.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Oculopharyngeal muscular dystrophy (OPMD) is a late on-
set disease due to trinucleotide or codon expansions in the gene
for the nuclear poly(A) binding protein, PABPN1, which con-
trols mRNA poly-adenylation [1,2]. OPMD symptoms are eye
lid drooping, swallowing diﬃculties and proximal limb weak-
ness, with the swallowing diﬃculties being usually the major
impairment. The disease is characterized by amyloid-like intra-
nuclear deposits consisting mainly of PABPN1 [3–6]. On the
level of the translation product, the codon expansions result
in the extension of a poly-alanine stretch which is directly posi-
tioned after the start methionine. In healthy individuals a*Corresponding author. Fax: +49 345 55 27 013.
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doi:10.1016/j.febslet.2008.04.002stretch of 10 alanine residues is observed, in OPMD patients
the homo-oligo-alanine segment can be expanded to maxi-
mally 17 alanine residues [7].
The in vitro analysis of amyloid-like deposit formation, as it
is observed in patient tissue, has so far been hampered by the
propensity of the full length protein to form non-ﬁbrillar,
amorphous aggregates. These aggregates most likely form be-
cause of the oppositely charged terminal domains indepen-
dently of the presence or absence of alanine extensions [8].
Therefore, in vitro ﬁbril formation was studied with the
N-terminal domain of PABPN1. The analyses revealed that
also the N-terminal domain of PABPN1 possessing the wild
type (N-WT) alanine segment of 10 residues forms ﬁbrils.
However, shorter lag phases and faster elongation rates were
obtained with the domain containing the most extreme exten-
sion observed in human, seven additional alanines (N-(+7)Ala)
[8,9]. Furthermore, ﬁbrils of N-WT and N-(+7)Ala diﬀer in
their morphology and resistance against solubilization [8,9].
The N-terminal domain of PABPN1 comprising 125 ami-
no acids lacks tertiary contacts both in its natural context
of the full-length protein and in the isolated form [10]. Re-
cent investigations by solid state NMR of the structure of
ﬁbrils formed by N-(+7)Ala suggest that the poly-alanine
segment is rigid in the ﬁbrils (Sackewitz et al., submitted
for publication). However, so far, no information exists
about the structural transition(s) which take place in the
N-terminal domain during conversion from the soluble to
the ﬁbrillar state. Monitoring ﬁbril formation of the N-ter-
minal domain N-(+7)Ala by ﬂuorescence spectroscopy is
not possible because of the lack of tryptophans. Thus, for
the analysis of ﬁbril formation, tryptophan residues were
introduced into and C-terminal of the poly-alanine segment.
Tryptophan ﬂuorescence studies have proven valuable ap-
proaches in analyses of ﬁbril formation: Insertions of trypto-
phans at diﬀerent positions of the Ab peptide enabled
ﬂuorescence studies during conversion from the soluble to
the ﬁbrillar state [11]. Tryptophan mutants (Y39W) of a-syn-
uclein [12] and b2-microglobulin [13] allowed as well com-
prehensive analyses of ﬁbril formation processes.
The tryptophan insertions into N-(+7)Ala allowed monitor-
ing ﬁbril formation by ﬂuorescence spectroscopy. Shifts of
tryptophan ﬂuorescence maxima were paralleled by the kinet-
ics of the decrease in acrylamide quench indicating that the
tryptophans become buried in a folded structure upon ﬁbrilblished by Elsevier B.V. All rights reserved.
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copy were matched by real-time NMR measurements in
which the disappearance of the tryptophan peak over time
was used as a tool to follow ﬁbril formation. Taken together,
our results indicate that ﬁbril formation of N-(+7)Ala can be
described as a two state conversion of a poorly structured or
even natively unfolded protein domain into the stably folded
ﬁbril without the existence of soluble pre-ﬁbrillar intermedi-
ates.2. Materials and methods
2.1. Recombinant expression constructs
For recombinant production in Escherichia coli cells, DNA coding
for the N-terminal fragment of PABPN1 with seven additional alanine
residues was expressed via pET15b, a vector which provides an N-ter-
minal His-tag [8,9]. Tryptophan residues were introduced via the Quik-
Change mutagenesis kit (Stratagene). For introducing the tryptophan
residue at position 11 (counted from the start methionine of the natu-
rally occurring protein with an alanine extension) primer 5 0-GCG
GCG GCA GCG GCA GCA TGG GCG GCG GCA GCA GCA
GCA-3 0, and for insertion at position 22, primer 5 0-GCA GCA
GCA GGA GCA GCA TGG GGA GGA AGA GGA TCA GGA-
3 0 and the complementary primers were used. The mutant constructs
were veriﬁed by DNA sequencing.2.2. Fibril formation and ﬁbril analysis
Fibrils were allowed to form at a protein concentration of 1 mM at
37 C in ﬁbrillation buﬀer (5 mM KH2PO4, 150 mM NaCl, pH 7.4).
Fibril formation was monitored by ANS ﬂuorescence as described
[9]. Not-ﬁbrillized protein was separated from ﬁbrillar species by cen-
trifugation for 1 h at 70,000 rpm. The supernatant was removed and
analysed immediately, the pellet was washed twice and resuspended
in the original volume of ﬁbrillation buﬀer.2.3. Far UV circular dichroism (CD) and ﬂuorescence measurements
CD spectra were recorded at 20 C on a Jasco J-810 CD-spectrom-
eter. Measurements were performed in 0.1 mm quartz cuvettes at a
protein concentration of 1 mg/ml in ﬁbrillation buﬀer. Excitation
and emission slit widths were 1 nm, the integration time was 1 s with
an increment of 1.0 nm. Spectra represent averages of seven scans
and are buﬀer-corrected. For ﬂuorescence measurements aliquots
(4 ll) of the washed and resuspended ﬁbril pellet, the supernatant or
the total ﬁbril sample were added to 800 ll ﬁbrillation buﬀer. Fluores-
cence spectra were recorded on a Jobin Yvon Spex Fluoromax 2 at
20 C upon excitation at 295 nm. Experiments were performed in
1 cm quartz cuvettes with excitation and emission slit widths of
5 nm, an integration time of 0.2 s and an increment of 1.0 nm. Spectra
represent averages of three scans and are buﬀer-corrected. To deﬁne
the ﬂuorescence maxima, weibull ﬁve parameters were ﬁt in sigma plot
to the spectra. Fits with R2 > 0.9 were used for ﬂuorescence maximum
determination.Fig. 1. (A) Scheme of the positions of the tryptophan insertions in the
N-terminal domain of PABPN1 with seven additional alanines and for
comparison, the naturally occurring N-terminal domain with the
alanine extensions, N-(+7)Ala. (B) Far UV CD analysis of the soluble
variants. Far UV CD spectra of W(11)-N-(+7)Ala (dashed-dotted
line), W(22)-N-(+7)Ala (dotted line) and N-(+7)Ala (solid line) were
recorded as described in Section 2.2.4. Acrylamide quenching
Not-ﬁbrillized protein was separated from ﬁbrillar species by centri-
fugation. Aliquots of the supernatant or of resuspended ﬁbrils were
added to 800 ll ﬁbrillation buﬀer to ﬁnal concentrations of 5 lM.
Subsequently, acrylamide was added to the samples at the indicated
ﬁnal concentrations. The intrinsic ﬂuorescence was recorded in ab-
sence (I0) and presence (I) of the quencher and I0/I plotted against
acrylamide concentration (Stern–Volmer plots). For monitoring ﬂuo-
rescence quenching by acrylamide during ﬁbrillation, aliquots of the
samples were removed at the indicated time points and diluted into
freshly prepared ﬁbrillation buﬀer containing 0.625 M acrylamide.
The protein concentration was 5 lM. Intrinsic ﬂuorescence signals
were recorded in the absence (I0) and presence (I) of the quencher
and the ratio I0/I was plotted against the incubation time. Quenching
was monitored by emission signals at 350 nm upon excitation at
295 nm.2.5. NMR spectroscopy
Proton spectra of W(22)-N-(+7)Ala were recorded at 37 C on a
Bruker Avance II 600 spectrometer. The ﬁbril formation kinetics were
measured in ﬁbrillation buﬀer with 1% (w/v) NaN3 in 90% H2O/10%
D2O. Eight hundred and sixty one-dimensional (1D)
1H spectra were
acquired over 110 h. Two further spectra were recorded after 400
and 615 h. The solvent resonance was suppressed by WATERGATE.
Data were processed and analysed using Felix 2.1. Several spectral re-
gions (0.7–1.0, 7.3–8.7, 10.1 ppm) were integrated and plotted against
the incubation time.
2.6. Miscellaneous
Recombinant protein expression and puriﬁcation, electron micros-
copy and monitoring ﬁbril formation kinetics were performed as de-
scribed [9].3. Results
3.1. Tryptophan insertions do not interfere with ﬁbril formation
of N-(+7)Ala
Tryptophan residues were introduced into N-(+7)Ala to gen-
erate chromophores which are sensitive to the polypeptide
environment and should thereby allow recording of the ﬁbril-
lation process by ﬂuorescence spectroscopy. Since it was not
clear whether the insertion of tryptophans would interfere with
ﬁbrillation, two insertion mutants were produced, W(11)-N-
(+7)Ala in which the tryptophan was in the middle of the oli-
go-alanine segment and W(22)-N-(+7)Ala with the chromo-
phore at a C-terminal position of the alanine stretch
(Fig. 1A). After recombinant production and puriﬁcation, sec-
ondary structural elements of the insertion variants were exam-
ined by far UV CD spectroscopy and compared to those of N-
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imposable demonstrating that the tryptophan neither in the
middle nor in the C-terminal position of the alanine stretchFig. 2. Fibril formation of the two tryptophan insertion mutants and
N-(+7)Ala. (A) Kinetics of ﬁbril formation of W(11)-N-(+7)Ala
(circles, dashed-dotted line) and W(22)-N-(+7)Ala (triangles, dotted
line) in comparison with N-(+7)Ala (squares, solid line). Fibril
formation was monitored by ANS ﬂuorescence. Sigmoidal curves
were ﬁtted to the ﬂuorescence intensities. (B) Electron micrograph of
ﬁbrils formed by W(11)-N-(+7)Ala after 9 days and (C) W(22)-N-
(+7)Ala after 13 days of incubation.causes a signiﬁcant change in the secondary structural ele-
ments.
Next, ﬁbril formation of W(11)-N-(+7)Ala and W(22)-N-
(+7)Ala was investigated by monitoring increases of ANS ﬂuo-
rescence. Unexpectedly, ﬁbril formation of the variants pro-
ceeded with faster elongation rates and shorter lag phases
than observed for N-(+7)Ala (Fig. 2A). The presence of amy-
loid-like structures was conﬁrmed by electron microscopy. The
ﬁbrils of both variants showed unbranched structures similar
to those formed by N-(+7)Ala (Fig. 2B and C).
3.2. Solvent exposure of the tryptophan residues changes upon
ﬁbril formation
In order to detect changes in solvent accessibility of the tryp-
tophan residues upon ﬁbril formation, ﬂuorescence spectra of
W(11)-N-(+7)Ala and W(22)-N-(+7)Ala were recorded during
ﬁbrillation and the ﬂuorescence maxima were determined
(Fig. 3). At early time points, the maximum of the ﬂuorescence
peak was at 358 nm indicating solvent exposure of the trypto-
phan residues as it is expected with a protein domain lacking
deﬁned tertiary contacts [14]. Upon prolonged incubation,
substantial blue shifts from 358 to 345 nm were observed.
Additionally, time-dependent increases in ﬂuorescence intensi-
ties at the new ﬂuorescence maxima at 345 nm were detected,
which correlated with the increases in ANS ﬂuorescence
(Fig. 2A). The blue shifts of ﬂuorescence maxima and the in-
creases of ﬂuorescence signals were interpreted by increases
in the hydrophobicity of tryptophan environment and burial
of these residues upon ﬁbrillation.
To analyse monomers and ﬁbrils separately, aliquots were
removed after various incubation intervals. The samples were
centrifuged, and supernatants (monomers) and resuspended
pellets (ﬁbrils) were analysed by ﬂuorescence spectroscopy.
The ﬂuorescence emission maxima of the supernatant and pel-
let fraction remained constant at 358 nm and 345/344 nm,
respectively (Fig. 4A). The data show that via ﬂuorescence
spectroscopy, the monomeric species can be discriminated
from the ﬁbrillar species. The stable ﬂuorescence maxima forFig. 3. Time-dependent changes of the spectroscopic properties of the
tryptophan insertion variants. Blue shifts of tryptophan ﬂuorescence
maxima of W(11)-N-(+7)Ala (black circles, dotted-dashed line) and
W(22)-N-(+7)Ala (black triangles, dotted line) are indicated on the left
ordinate. Increases of tryptophan ﬂuorescence intensities at 344/
345 nm of W(11)-N-(+7)Ala (open circles, dotted-dashed line) and
W(22)-N-(+7)Ala (open triangles, dotted line) are shown on the right
ordinate. Curves were ﬁtted to obtain sigmoidal shapes.
Fig. 4. Changes in the intrinsic tryptophan ﬂuorescence of the
separated monomeric and ﬁbrillar species. (A) Plot of the tryptophan
ﬂuorescence maximum versus the incubation time of W(11)-N-
(+7)Ala, supernatant (open circles), ﬁbrils (closed circles). Tryptophan
ﬂuorescence signals of W(22)-N-(+7)Ala, supernatant (open triangles),
ﬁbrils (closed triangles). (B) Time-dependent decrease of the trypto-
phan ﬂuorescence intensities in the soluble fraction, W(11)-N-(+7)Ala
(open circles, dashed-dotted line) and W(22)-N-(+7)Ala (open trian-
gles, dotted line) at 358 nm and increases of intensities in the ﬁbrils
(W(11)-N-(+7)Ala, closed circles; W(22)-N-(+7)Ala, triangles) at 345,
344 nm. Curves were plotted to obtain sigmoidal shapes.
Fig. 5. Fluorescence quench by acrylamide. (A) The ratio of trypto-
phan ﬂuorescence at 350 nm in absence (I0) and presence (I) of
acrylamide was plotted against increasing concentrations of acrylam-
ide. Fibrils (closed symbols) and soluble protein (open symbols) of
W(11)-N-(+7)Ala (circles, dotted-dashed lines) and W(22)-N-(+7)Ala
(triangles, dotted lines). (B) and (C) Time-dependent decreases of I0/I
and ﬂuorescence maxima of W(11)-N-(+7)Ala (closed circles) (B) and
W(22)-N-(+7)Ala (closed triangles) (C). Shifts of ﬂuorescence maxima
are indicated by the open symbols. Fluorescence quenching by
acrylamide was analysed at 350 nm and an acrylamide concentration
of 0.625 M. All curves were ﬁtted for sigmoidal shapes.
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phan environment. The time-dependent decrease of the ﬂuo-
rescence intensity of the soluble species at 358 nm
corresponded to the increase of ﬂuorescence intensity at 344/
345 nm of the insoluble fraction (Fig. 4B). Thus, a direct con-
version of the soluble protein into ﬁbrillar species without sol-
uble intermediate states can be envisaged.
3.3. Acrylamide quenching of tryptophan ﬂuorescence decreases
during ﬁbril formation
Solvent accessibility of the tryptophans was measured by
acrylamide quenching. First the acrylamide concentration
which was required for quenching was determined by adding
increasing concentrations of acrylamide to monomeric and
ﬁbrillar fractions. The concentration-dependent ﬂuorescence
quench of the soluble species was visualized by Stern–Volmer
plots (Fig. 5A). In contrast to the soluble species, the ﬁbrillar
fractions of both tryptophan variants did not display a signif-
icant ﬂuorescence quench indicating that the tryptophans areno longer solvent exposed in the ﬁbrils. Thus, ﬁbrillation kinet-
ics were monitored by acrylamide quenching analysis. The
time-dependent changes in ﬂuorescence quenches were ana-
lysed in the presence of 0.625 M acrylamide (Fig. 5B and C).
The kinetics of the reduction in the acrylamide quenches cor-
relate roughly with the slightly delayed kinetics of tryptophan
blue shifts.
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formation
For detailed investigations of the structural changes in
W(22)-N-(+7)Ala during ﬁbril formation, a time resolved
NMR experiment was performed. Liquid state NMR allows
only to detect 1H resonances of protein protons, if the poly-
peptide chain tumbles fast enough to average out the dipolarFig. 6. Real-time NMR analysis of ﬁbril formation of W(22)-N-
(+7)Ala. (A) Low ﬁeld sections of 1D 1H NMR spectra of W(22)-N-
(+7)Ala at the beginning (top), after 110 h (middle), and at the end of
the ﬁbrillation experiment (bottom) at 37 C. (B) Decay of 1D 1H
NMR resonances of W(22)-N-(+7)Ala during ﬁbril formation. Rela-
tive NMR integrals of the amide region (triangles, 7.3–8.7 ppm),
methylene/methyl group region (diamonds, 0.7–1.0 ppm) and the
single tryptophan side chain resonance (closed circles, 10.1 ppm).
For the decrease of NMR integrals, a single exponential function
between 75 and 620 h was assumed (solid lines). Open circles represent
the relative ANS ﬂuorescence increase according to Fig. 2A using
inverse y-scaling.couplings. This is the case for all protons of W(22)-N-
(+7)Ala at a monomeric or low oligomeric state and for pro-
tons of the chains, which stick out from the ﬁbrils into the
solution. This structural information is converse to solid state
NMR analyses employing cross-polarization, where only reso-
nances are detectable for nuclei with restricted motions inside
the ﬁbrils (Sackewitz et al., submitted for publication). In the
real-time NMR experiment presented here, 860 1D 1H NMR
spectra in solution were recorded during 615 h of ﬁbrillation
(Fig. 6A). The ﬁrst 1D 1H NMR spectrum of W(22)-N-
(+7)Ala recorded immediately after initiation of the ﬁbrillation
reaction by dissolving the protein, resembles very closely that
of N-(+7)Ala [10] with an additional, well resolved resonance
at 10.1 ppm from the He1 proton of the tryptophan side chain.
It represents the spectrum of a fully unfolded protein. To fol-
low the time course of diﬀerent resonances, the spectral regions
of methylene/methyl groups, amides and the He1 proton were
integrated and plotted against the incubation time (Fig. 6B).
All kinetics show a lag phase of ca. 50 h followed by an expo-
nential decay. The integrals decay, because the number of sol-
uble, fast tumbling protein molecules decreases. This time
course is consistent with the ﬁbril formation experiments fol-
lowed by ANS ﬂuorescence. Interesting is the appearance of
the last 1H NMR spectrum after the ﬁbrillation had ﬁnished.
The signal of the tryptophan side chain disappeared almost
completely (Fig. 6A and B), whereas amide and methylene/
methyl protons show remaining signals with ca. 20% of the ini-
tial integral value. These data suggest that the tryptophan res-
idue of W(22)-N-(+7)Ala is positioned closely to the poly-
alanine stretch, which forms the core of the ﬁbril and therefore
restricts the local motions. The remaining signals belong to
C-terminal part of the polypeptide chains sticking out into
the solution with suﬃcient ﬂexibility.4. Discussion
Mutational approaches have proven useful tools to probe
amyloid formation [12,13,15,16]. Though the exchanges are
likely to modify certain facets of the molecular transitions dur-
ing ﬁbril formation and the ﬁbril structure itself, this approach
is legitimated by the occurrence of natural exchanges in amy-
loidogenic proteins or their peptides such as Alzheimer peptide
or a-synuclein [17–19].
Here, ﬁbril formation of the N-terminal domain of PABPN1
was monitored with tryptophan insertion mutants. The trypto-
phan residues which had been introduced into the poly-alanine
segment did not suppress ﬁbril formation, rather ﬁbril forma-
tion was accelerated, a fact that could be explained by the high
hydrophobicity of tryptophans and their propensity to form
b-strands [20]. Thus, the tryptophans could lower activation
energies from the soluble to the insoluble state. Though non-
ﬁbrillar, oligomeric deposits of the tryptophan variants have
been never observed by electron microscopy, we cannot com-
pletely exclude the unlikely existence of insoluble intermedi-
ate(s).
Since after ﬁbril formation ﬂuorescence blue shifts were ob-
served and acrylamide quenching was no longer detectable, the
tryptophans must be integrated into the b-core structure of the
ﬁbrils. Of course, on the atomic level, the ﬁbrillar structures of
both tryptophan insertion variants are presumably diﬀerent
from those of N-(+7)Ala due to the packing of the large
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N-(+7)Ala and the wild type fragment containing 10 alanine
residues diﬀer in their morphology and chemical properties
[9], diﬀerences between ﬁbrils of the tryptophan insertion vari-
ants and the unaltered N-terminal domain are to be expected.
Nevertheless, the tryptophan insertions allowed characteriza-
tion of the ﬁbril formation process by ﬂuorescence spectro-
scopy and by real-time NMR. Both techniques show that the
tryptophans at position 11 and 22 are part of the b-cross struc-
ture of the ﬁbrils and they are not solvent-accessible anymore.
This result conﬁrms earlier ﬁndings of our group which indicate
that the poly-alanine segment is rigid and protease-protected in
the ﬁbrils (Sackewitz et al., submitted for publication). Fibril
formation kinetics detected by real-time NMR matched those
recorded by the ﬂuorescence approach. However, via real-time
NMR, a considerably more accurate description of the conver-
sion kinetics is possible than by the ﬂuorescence studies. The
NMR kinetic data indicate that no soluble kinetic intermedi-
ate(s) is populated during ﬁbrillation. Furthermore, in several
preliminary experiments, ﬁbril formation was monitored by
real-time NMR with natural N-(+7)Ala lacking the trypto-
phan insertion (data not shown). However, for these studies ﬁ-
bril formation had to be seeded, since unseeded ﬁbrillation
required measurements of approx. 20–30 days. Also with these
seeded samples, biphasic signal decays, which would indicate a
soluble intermediate have never been detected.
Taken together, these results imply that ﬁbril formation of
the N-terminal domain of PABPN1 does not resemble that
of a-synuclein, which also slowly converts from a natively
unfolded structure into amyloid-like ﬁbrils, however, via the
transient formation of non-ﬁbrillar oligomeric structures
[21].
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